logo-loader

AstraZeneca submits supplemental new drug application for Tagrisso in Japan

Published: 07:34 27 Nov 2017 GMT

lung
Tagrisso oral tablets have been approved in more than 60 countries

AstraZeneca PLC (LON:AZN) has submitted a supplemental new drug application in Japan for lung cancer treatment Tagrisso.

Following positive phase III trial results, the company has sent its request to Japan's Pharmaceuticals and Medical Devices Agency for the use of Tagrisso for first-line treatment of patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). 

READ: AstraZeneca shares up 1.2% after getting regulatory green light for asthma drug

The phase III Flaura trial showed Tagrisso significantly improved progression-free survival compared to treatments erlotinib or gefitinib in previously untreated patients with locally-advanced or metastatic EGFR mutation-positive NSCLC.

READ: AstraZeneca lifts full-year core earnings guidance

Tagrisso 40mg and 80mg once-daily oral tablets have been approved in more than 60 countries, including the US, the European Union, Japan and China for patients with EGFR T790M mutation-positive advanced NSCLC.

FTSE rises ahead of Easter weekend, JD Sport gains on upbeat outlook -...

The FTSE 100 gained on the final morning of this shortened Easter trading week. Festive cheer was limited though, as Thames Water confirmed shareholders would not provide it with a £500 million rescue package, prompting speculation over the London supplier’s future. On a more positive...

1 hour, 42 minutes ago